Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine

Diabetic Medicine

Volumn 25, Issue 2, 2008, Pages 200-205

  Moses, A C ^a   Raskin, P ^b   Khutoryansky, N ^a  

^a NOVO NORDISK INC   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Basal; Glycaemic control; Insulin analogues; Target; Type 2 diabetes

Indexed keywords

1,5 ANHYDROSORBITOL; BIPHASIC INSULIN; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; PIOGLITAZONE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGIC STUDIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 39749118072     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02384.x     Document Type: Article

References (15)

1. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S et al. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006 29 : 1214 1219.
2. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 2003 5 : 355 363.
3. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a US trial of the GlycoMark assay. Diabetes Care 2004 27 : 1859 1865.
4. Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG. Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta 2004 350 : 201 209.
5. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P et al. Initiating insulin therapy in Type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 265.
6. GlycoMark™. Package insert. Available at http://www.glycomark.com/ product_information.asp Last accessed 25 October 2007.
7. Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with Type 2 diabetes - results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 2006 21 : 2166 2171.
8. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005 54 : 1 7.
9. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. J Am Med Assoc 2006 295 : 1681 1687.
10. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes. Diabetologia 2001 46 : M9 M16.
11. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. J Am Med Assoc 2003 290 : 486 494.
12. Ceriello A, Quagliana L, Catone B, Pascon R, Piazzola M, Bais B et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002 25 : 1439 1443.
13. Esposito K, Giugliano D, Nappo F, Marfella R, Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation 2004 110 : 214 219.
14. Brownlee M. The pathophysiology of diabetic complications: a unifying mechanism. Diabetes 2005 54 : 1615 1625.
15. 1c-independent risk factor for diabetic complications. J Am Med Assoc 2006 295 : 1707 1708.